Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight)

Published:2018-06-01 Issue:8 Volume:73 Page:2129-2136
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Molina Jean-Michel¹²,Gallien Sebastien³,Chaix Marie-Laure⁴²,El Abbassi El Mountacer⁵,Madelaine Isabelle⁶,Katlama Christine⁷,Valin Nadia⁸,Delobel Pierre⁹,Desseaux Kristell²,Peytavin Gilles¹⁰,Saillard Juliette¹¹,Raffi François¹²,Chevret Sylvie²⁵,Ponscarme D,Lascoux C,Girard P M,Rami A,Yazdanpanah Y,Simon A,Tubiana R,Duvivier C,Jeantils V,Loreillard D,Poizot-Martin I,Bernard L,Gras G,Allavena C,Bernaud C,Bouchez S,Hall N,Reliquet V,Raffi F,De Truchis P,Charreau I,Bocquet L,Lemoing V,Point G,Molina J M,Chevret S,El Abbassi E M,Gallien S,Tattevin P,Gras G,Chaix M L,Peytavin G,Saillard J,Couffin-Cadiergues S,Madelaine I,Diallo A,Gibowski S,

Affiliation:

1. Department of Infectious Diseases, Saint-Louis Hospital, AP-HP, Paris, France

2. University of Paris Diderot, Sorbonne Paris University, Paris, France

3. Department of Immunology and Infectious Diseases, Henri-Mondor Hospital, Creteil, France

4. Laboratory of Virology, Saint-Louis Hospital, AP-HP, Paris, France

5. Department of Biostatistics, Saint-Louis Hospital, AP-HP, Paris, France

6. Pharmacy, Saint-Louis Hospital, AP-HP, Paris, France

7. Department of Infectious Diseases, Pitié Salpêtrière Hospital, Paris, France

8. Department of Infectious Diseases, Saint-Antoine Hospital, Paris, France

9. Department of Infectious Diseases, Toulouse University Hospital, Toulouse, France

10. Department of Pharmacology, Bichat Hospital, Paris, France

11. ANRS, Paris, France

12. Infectious Disease Department and INSERM CIC 1413, University Hospital of Nantes, Nantes, France

Funder

ANRS

French National Agency for Research on AIDS and viral hepatitis

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/73/8/2129/25178842/dky181.pdf

Reference36 articles.

1. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015;GBD 2015 HIV Collaborators;Lancet HIV,2016

2. Efficacy and safety of once-daily regimens in the treatment of HIV infection;Molina;Drugs,2008

3. Better adherence with once-daily antiretroviral regimens: a meta-analysis;Parienti;Clin Infect Dis,2009

4. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial;Orkin;Lancet HIV,2018

5. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial;Margolis;Lancet,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance;Journal of Antimicrobial Chemotherapy;2023-04-27

2. Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update;Southern African Journal of HIV Medicine;2020-09-16

3. Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations;Clinical Pharmacokinetics;2020-07-22

4. Once‐daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS ‐165 DARULIGHT study;British Journal of Clinical Pharmacology;2018-11-12

5. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study;Journal of Antimicrobial Chemotherapy;2018-06-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3